《醫(yī)學(xué)交流課件：下肢動(dòng)脈腔內(nèi)成形術(shù)現(xiàn)狀及展望》由會(huì)員分享，可在線閱讀，更多相關(guān)《醫(yī)學(xué)交流課件：下肢動(dòng)脈腔內(nèi)成形術(shù)現(xiàn)狀及展望（31頁(yè)珍藏版）》請(qǐng)?jiān)谘b配圖網(wǎng)上搜索。
1、Armstrong EJ,Saeed H, Alvandi B, et al. J Endovasc Ther. 2014; 21: 34-43Armstrong EJ,Saeed H, Alvandi B, et al. J Endovasc Ther. 2014; 21: 34-43Saxon R, Chervu A, Jones P, et al. J Vasc Interv Radiol. 2013;24:165174.Lammer J, Zeller T, Hausegger K, et al. J Am Coll Cardiol. 2013;62:1320-1327Diamanto
2、poulos A;Katsanos K. J Cardiovasc Surg .2014V55N5:655-65 6RCT 287患者,328處股腘動(dòng)脈閉塞性病變Diamantopoulos A;Katsanos K. J Cardiovasc Surg .2014V55N5:655-65 Marmagkiolis K, Hakeem A, Choksi N, et al. Catheter Cardiovasc Interv.2014V84N4 :555-64Marmagkiolis K, Hakeem A, Choksi N, et al. Catheter Cardiovasc Inte
3、rv.2014V84N4 :555-64研究/器械患者數(shù)量平均病變長(zhǎng)度12 個(gè)月內(nèi)的一期通暢率12 個(gè)月內(nèi)支架折斷率DURABILITY-2001Protg Everflex100242 mm64.8%6.0%STELLA Registry2LifeStent58220 mm66.0%17.7%Zilver PTX Global RegistryZilver PTX3135226 mm77.6%2.1%STELLA PTXZilver PTX445252 mm52.5%9.0%Viabahn TASC C&DViabahn571265 mm67.0%0.0%SUPERB 500Supera61
4、72223 mm80.5%0.0%圣路易斯大學(xué)Supera742279 mm80.1%0.0%1. Bosiers M, et al., Results of the Protg EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg. 2011;54:1042-50. 2. Davaine JM, et al., One-year clinical outcome after primary stenting for Trans-Atlantic Inter-S
5、ociety Consensus (TASC) C and D femoropopliteal lesions (the STELLA “STEnting Long de LArtre fmorale superficielle” cohort). Eur J Vasc Endovasc Surg. 2012;44:432-41. 3. Bosiers M, et al., Zilver PTXS-ASI. The Zilver PTX Single Arm Study: 12-month results from the TASC C/D lesion subgroup. J Cardiov
6、asc Surg (Torino). 2013;54:115-22. 4. DavaineJM et al., Treatment of TASC C and D Femoropoliteal Lesions with Paclitaxel eluting Stents: 12 month Results of the STELLA-PTX Registry Eur J Vasc Endovasc Surg (2015) -, 1-7 5. ZellerT, et al., Heparin-Bonded Stent-Graft for the Treatment of TASC II C an
7、d D Femoropopliteal Lesions: The Viabahn-25 cm Trial J ENDOVASC THER 2014;21:765774 6. Werner, et al., Treatment of complex atherosclerotic femoropopliteal artery disease with a self-expanding nitinol stent: midterm results for the Leipzig SUPERA 500 registry, EuroIntervention 2014:10:861-868. 7. Br
8、escia, et al., Stenting of femoropopliteal lesions using interwoven nitinol stents, J Vasc Surg. 2015 Mar 6. pii: S0741-5214(15)00132-9.不同試驗(yàn)描述的不同數(shù)據(jù)可能沒(méi)有統(tǒng)計(jì)學(xué)差異和臨床意義，不同臨床試驗(yàn)包括了不同特征患者群體。30 days6 Months 9 Months12 Months初級(jí)通暢率100 %91 %89 %87 %次級(jí)通暢率100 %100 %96 %92 %免于TLR100 %95 %93%89%免于截肢100 %100 %100 %100 %支架斷裂0%0%0%0%REALISTICREALISTIC trial trial ( (smartflexsmartflex) )39
醫(yī)學(xué)交流課件：下肢動(dòng)脈腔內(nèi)成形術(shù)現(xiàn)狀及展望
